Ultrahuman as India's Oura

Ultrahuman matters because it shows the smart ring market is now big enough for a serious fast follower, but still fragile enough that one patent loss can shut off growth overnight. The company found a better wearable wedge by leaving glucose patches for a ring people can wear every day, then copied Oura’s playbook with hardware first and a growing software layer, but at a much smaller scale and with heavier dependence on one product and one market reopening.1 2 3 4

• Ultrahuman started with glucose patches that showed how meals affected blood sugar, then pivoted in 2022 to rings because patches were harder to wear continuously and produced a weaker habit loop for mainstream consumers. Oura later moved the other direction, adding glucose integration into its ring centered health app.1 3
• The monetization split is the clearest contrast. Ultrahuman sells a $349 ring with core analytics included, then upsells small add ons like ovulation and AFiB features, with 12% of users paying. Oura proved the larger prize, with about 80% of 2024 revenue from rings and 20% from subscriptions, and 2M paying subscribers.1 3
• Scale remains the gap. Ultrahuman was at about $69M in fiscal 2026 revenue and $19.9M through June 2026 after the U.S. import block. Oura was at $1.4B in trailing revenue as of June 2026, while Whoop reached $1.1B in annualized bookings in 2025, showing how far the leaders are ahead in brand, distribution, and recurring revenue.1 2 4 5

From here, the category is moving toward health subscriptions layered on top of passive hardware. Ultrahuman’s path is to rebuild U.S. distribution with Ring PRO, raise Power Plug attach, and turn a lower price, no mandatory subscription position into a wider health platform before Oura and Whoop lock up the market’s software and clinical partnerships.1 4 5